Hans Prenen

14.9k total citations · 4 hit papers
207 papers, 8.6k citations indexed

About

Hans Prenen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hans Prenen has authored 207 papers receiving a total of 8.6k indexed citations (citations by other indexed papers that have themselves been cited), including 142 papers in Oncology, 59 papers in Pulmonary and Respiratory Medicine and 43 papers in Molecular Biology. Recurrent topics in Hans Prenen's work include Colorectal Cancer Treatments and Studies (62 papers), Gastric Cancer Management and Outcomes (29 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Hans Prenen is often cited by papers focused on Colorectal Cancer Treatments and Studies (62 papers), Gastric Cancer Management and Outcomes (29 papers) and Cancer Immunotherapy and Biomarkers (27 papers). Hans Prenen collaborates with scholars based in Belgium, United States and France. Hans Prenen's co-authors include Eric Van Cutsem, Xavier Sagaert, Baki Topal, Karin Haustermans, Massimiliano Mazzone, Mario Di Matteo, Maria Dêbiec‐Rychter, Josep Tabernero, Raf Sciot and A. van Oosterom and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Hans Prenen

197 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gastric cancer

2016 1.4k citations Eric Van Cutsem, Xavier Sagaert et al. profile →
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen

2012 986 citations Eric Van Cutsem, Josep Tabernero et al. Journal of Clinical Oncology profile →
MET is required for the recruitment of anti-tumoural neutrophils

2015 378 citations Hans Prenen et al. profile →
The potential and controversy of targeting STAT family members in cancer

2019 273 citations Yannick Verhoeven, Delphine Quatannens et al. profile →

Peers

Countries citing papers authored by Hans Prenen

Since Specialization

Citations

This map shows the geographic impact of Hans Prenen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Prenen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Prenen more than expected).

Fields of papers citing papers by Hans Prenen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Prenen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Prenen. The network helps show where Hans Prenen may publish in the future.

Co-authorship network of co-authors of Hans Prenen

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Prenen. A scholar is included among the top collaborators of Hans Prenen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Prenen. Hans Prenen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: multicenter study using natural language processing on Belgian hospital data 2025 ·PubMed ·(unknown), Clara L. Oeste, Vincent Geldhof, Lieselot Croes, (unknown), Annelies Verbiest, (unknown), (unknown), Constantijn Franssen, Philip R. Debruyne, Hans Prenen, (unknown), Johan De Sutter, Christof Vulsteke	2
2	Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition 2024 ·Journal of Experimental & Clinical Cancer Research ·Christophe Deben, Laurie Freire Boullosa, (unknown), Edgar Cardenas De La Hoz, (unknown), (unknown), Marc Peeters, Steve Vanlanduit, Abraham Lin, Krijn K. Dijkstra, Paul Van Schil, Jeroen Hendriks, Hans Prenen, Geert Roeyen, Filip Lardon, Evelien Smits	8
3	Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays 2024 ·Communications Biology ·Christophe Deben, Edgar Cardenas De La Hoz, (unknown), (unknown), (unknown), Steve Vanlanduit, (unknown), (unknown), Nelson Dusetti, Abraham Lin, Geert Roeyen, Marc Peeters, Hans Prenen, Filip Lardon, Evelien Smits	3
4	Combining immunotherapy and radiation therapy in gastrointestinal cancers: A review 2024 ·Critical Reviews in Oncology/Hematology ·(unknown), (unknown), Hans Prenen, Maria Antonietta Gambacorta, Paul N. Span, Philip Poortmans	2
5	Sotorasib plus panitumumab for pre-treated non-small cell lung cancer with KRASG12C mutation: A phase 1b study. 2024 ·Journal of Clinical Oncology ·Corey J. Langer, Rachel Galot, Hans Prenen, David S. Hong, Iván Victoria, Ravi Salgia, Maxime Chénard-Poirier, Muhammad Furqan, Emily Chan, (unknown), Caihong Xia, Bob T. Li	1
6	Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: Pooled analysis of RAGNAR and LUC2001 studies. 2024 ·Journal of Clinical Oncology ·Shubham Pant, Joon Oh Park, Wu‐Chou Su, Martin Schüler, (unknown), Gopa Iyer, Toshihiko Doi, Shukui Qin, Josep Tabernero, Hans Prenen, Gunnar Folprecht, Helen Winter, Graziela Zibetti Dal Molin, Hussein Sweiti, (unknown), Constance Hammond, Huimin Liao, Shibu Thomas, Spyros Triantos, Yin‐Hsun Feng	1
7	POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis 2024 ·Neuro-Oncology Advances ·Alexander M. Menzies, Georgina V. Long, (unknown), Hussein A. Tawbi, Jeffrey S. Weber, Keith T. Flaherty, Grant A. McArthur, Paolo A. Ascierto, (unknown), Karl D. Lewis, Katy K. Tsai, Omid Hamid, Hans Prenen, Luis Fein, Erjian Wang, (unknown), Fan Zhang, Joseph F. Kleha, Alessandra di Pietro, Michael A. Davies	1
8	665P First-in-human, phase Ia/b, dose-escalation/expansion study of KRAS G12C inhibitor BI 1823911, as monotherapy and combined with anticancer therapies, in patients (pts) with advanced or metastatic solid tumours harbouring a KRAS G12C mutation 2023 ·Annals of Oncology ·John V. Heymach, Nuria Kotecki, Hans Prenen, Guzmán Alonso, Colin R. Lindsay, Minal Barve, Claus Thamer, (unknown), Marcelo Marotti, (unknown)	10
9	P-95 Long-term effectiveness results and prognostic predictors for overall survival from CIREL – the real-world multi-centre, observational cohort on irinotecan-eluting transarterial chemoembolization in CRLM 2023 ·Annals of Oncology ·Hans Prenen, Dirk Arnold, Bruno Sangro, Bleranda Zeka, (unknown), (unknown), Roberto Iezzi, Philippe L. Pereira, Julien Taı̈eb	0
10	1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial 2023 ·Annals of Oncology ·Shubham Pant, Dirk Arnold, Josep Tabernero, Yohann Loriot, Gunnar Folprecht, Georg Martin Haag, Daniel H. Palmer, Hans Prenen, Jermaine Coward, Iwona Ługowska, (unknown), Andrés Cervantes, Martin Gutierrez, Hussein Sweiti, Constance Hammond, (unknown), Shibu Thomas, Spyros Triantos, (unknown), (unknown)	2
11	622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·David J. Pinato, Ruth Plummer, Martin Gutierrez, Jeffrey Yachnin, (unknown), Martin Højgaard, Knut B. Smeland, William J. Edenfield, Hans Prenen, Lars Ny, Alan Anthoney, Nuria Kotecki, Stefan N. Symeonides, Louis Viviers, (unknown), (unknown), Udai Banerji	3
12	734 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099280, in patients with select advanced solid tumors 2022 ·Regular and Young Investigator Award Abstracts ·Hans Prenen, Thierry Lesimple, Marie E. Robert, (unknown), Jean‐Pascal Machiels, Tarek Meniawy, Eric Van Cutsem, Nuria Kotecki, Sarina A. Piha‐Paul, Michael T. Schweizer, Shirish M. Gadgeel, (unknown), Louis Viviers, (unknown), Antoîne Italiano	2
13	529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors 2021 ·SHILAP Revista de lepidopterología ·Eric Van Cutsem, Hans Prenen, (unknown), Kristen Spencer, Tara C. Mitchell, Howard A. Burris, Nuria Kotecki, Rebecca Kristeleit, David J. Pinato, Solmaz Sahebjam, Donna M. Graham, Thomas B. Karasic, (unknown), Kevin O’Hayer, Ryan Geschwindt, Sarina A. Piha‐Paul	11
14	Cancer-Associated Fibroblasts as a Common Orchestrator of Therapy Resistance in Lung and Pancreatic Cancer 2021 ·Cancers ·Andreas Domen, Delphine Quatannens, Sara Zanivan, Christophe Deben, Jonas R.M. Van Audenaerde, Evelien Smits, An Wouters, Filip Lardon, Geert Roeyen, Yannick Verhoeven, Annelies Janssens, Timon Vandamme, Peter A. van Dam, Marc Peeters, Hans Prenen	42
15	Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects 2020 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Hans Prenen, Eva Segelov	1
16	Comparison of multiple protein extraction buffers for GeLC-MS/MS proteomic analysis of liver and colon formalin-fixed, paraffin-embedded tissues 2015 ·Molecular BioSystems ·(unknown), Kurt Boonen, (unknown), Xavier Sagaert, Hans Prenen, Bart Landuyt, Liliane Schoofs, Evelyne Maes	25
17	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer 2014 ·Clinical Cancer Research ·Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Ірина Давиденко, Joe Stephenson, Élena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero	92
18	Proteomic analysis of formalin-fixed paraffin-embedded colorectal cancer tissue using tandem mass tag protein labeling 2013 ·Molecular BioSystems ·Evelyne Maes, Dirk Valkenborg, Inge Mertens, (unknown), Geert Baggerman, Xavier Sagaert, Bart Landuyt, Hans Prenen, Liliane Schoofs	19
19	Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen breakdown → 2012 ·Journal of Clinical Oncology ·Eric Van Cutsem, Josep Tabernero, Radek Lakomý, Hans Prenen, Jana Prausová, Teresa Macarulla, Paul Ruff, Guy A. Van Hazel, Vladimir Moiseyenko, David Ferry, Joe McKendrick, Jonathan Polikoff, Alexia Tellier, R Castan, Carmen J. Allegra	986
20	PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer 2009 ·Clinical Cancer Research ·Hans Prenen, Jef De Schutter, Bart Jacobs, Wendy De Roock, Bart Biesmans, Bart Claes, Diether Lambrechts, Eric Van Cutsem, Sabine Tejpar	241

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact